INDIVIOR PLC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Total Compensation for the Chair and Non-Executive Directors
The table below sets out the total remuneration received by the Chair and the Non-Executive Directors for the year ended December 31, 2024.
| 2024(1) | |
| ’000 | |
|---|---|
| Dr. David Wheadon(2) | $76.5 |
| Juliet Thompson | £119.5 |
| Peter Bains | £99.3 |
| Joe Ciaffoni(3) | $4.0 |
| Dr. Keith Humphreys | $131.4 |
| Jo LeCouilliard | £99.9 |
| Barbara Ryan | $146.6 |
| Robert Schriesheim(3) | $4.0 |
| Mark Stejbach | $162.4 |
| Graham Hetherington(4) | £282.7 |
| Jerome Lande(4)(5) | $109.1 |
| Dr. A. Thomas McLellan(6) | $20.4 |
Note: Daniel Ninivaggi was appointed as an Independent Non-Executive Director and as a member of the Nomination Committee on January 31, 2025. As such, he did not receive any fees in 2024.
(1)The amounts include fees and benefits. Fees are paid in their local currency. Since 2016, a fixed exchange rate (GB£1:U.S.$1.4434) has been applied to translate U.K. amounts into U.S. dollars, effectively setting fees at that time, on both a U.K. and U.S. basis. Benefits comprise the grossed-up cash value of travel and subsistence costs incurred in the normal course of business in relation to attendance at Board meetings held in the U.K. and in fulfilling the Non-Executive Director’s role, and the cost of providing professional support for the completion of U.K. tax returns for U.S. tax residents; these costs were translated to U.S. dollars using the average exchange rate for the 2024 financial year (GB£1:U.S.$1.2782).
(2)Dr. Wheadon was appointed as an Independent Non-Executive Director and as a member of the Compensation, Nomination, and Science Committees on June 1, 2024. The fee shown for 2024 is from the date of his appointment to December 31, 2024. Dr. Wheadon was subsequently appointed as Chair of the Board and Chair of the Nomination Committee on January 28, 2025.
(3)Mr. Ciaffoni and Mr. Schriesheim were each appointed as an Independent Non-Executive Director and as a member of the Nomination Committee on December 17, 2024. The fee shown for each for 2024 is from the date of their appointment to December 31, 2024.
(4)Mr. Hetherington and Mr. Lande retired from the Board on December 31, 2024.
(5)Mr. Lande stepped down as a member of the Nomination Committee on May 31, 2024.
(6)Dr. McLellan retired from the Board on February 29, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.